Hemispherx Says FDA Will Accept Ampligen Analyses
Hemispherx Biopharma Inc. said Wednesday that regulators will accept and review new analyses of data from a Phase III clinical trial of its chronic fatigue syndrome drug Ampligen, which could relieve...To view the full article, register now.
Already a subscriber? Click here to view full article